Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€64.41

€64.41

3.090%
1.93
3.090%
€115.81

€115.81

 
19.09.24 / Tradegate WKN: A0D9T1 / Symbol: DXCM / Name: DexCom / Stock / Healthcare Equipment & Supplies / Large Cap /
Latest predictions
€80.59
26.08.24
-2.41%
buy
€89.94
23.08.24
-1.42%
buy
€110.50
26.07.24
9.30%
buy
€105.83
26.07.24
10.88%
buy
€87.43
26.07.24
10.88%
buy
€82.88
26.07.24
10.42%
buy
Your prediction

Dexcom Inc. Stock

Dexcom Inc. dominated the market today, gaining €1.93 (3.090%).
With 25 Buy predictions and not a single Sell prediction Dexcom Inc. is an absolute favorite of our community.
As a result the target price of 115 € shows a very positive potential of 78.54% compared to the current price of 64.41 € for Dexcom Inc..
For the coming years our community has positive and negative things to say abot the Dexcom Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.

Pros and Cons of Dexcom Inc. in the next few years

Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Dexcom Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Dexcom Inc. 3.090% 3.603% -8.117% -26.973% -42.471% -46.303% 83.687%
Zimmer Holdings 0.060% 1.600% -4.274% -15.241% -12.236% -22.302% -25.058%
Dentsply Sirona Inc. 0.750% 5.098% 4.688% -26.998% -25.047% -53.793% -46.578%
Teleflex Inc. 0.930% 0.000% 2.830% 11.795% -1.802% -32.298% -28.513%

Comments

Prediction Buy
Perf. (%) -2.41%
Target price 80.586
Change
Ends at 26.08.25

DexCom, Inc. (NASDAQ: DXCM) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $90.00 price target on the stock.
Ratings data for DXCM provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -1.42%
Target price 89.940
Change
Ends at 23.08.25

DexCom, Inc. (NASDAQ: DXCM) had its price target raised by analysts at Stifel Nicolaus from $90.00 to $100.00. They now have a "buy" rating on the stock.
Ratings data for DXCM provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 9.30%
Target price 110.496
Change
Ends at 26.07.25

DexCom, Inc. (NASDAQ: DXCM) had its price target lowered by analysts at BTIG Research from $156.00 to $120.00. They now have a "buy" rating on the stock.
Ratings data for DXCM provided by MarketBeat
Show more

News

Dexcom Brings Mentorship to Centerfield, Welcomes New, Star Athletes to Its Ground-breaking NIL Program Dexcom U: https://mms.businesswire.com/media/20240918060382/en/2246397/5/ROSTER_DEXU-2024_16x9_v4_STILL.jpg
Dexcom Brings Mentorship to Centerfield, Welcomes New, Star Athletes to Its Ground-breaking NIL Program Dexcom U


DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company’s

2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200: https://g.foolcdn.com/editorial/images/790278/patient-and-doctor-talking.jpg
2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200

With $200, one can afford many lottery tickets, one of which could be a winner. However, the odds of winning meaningful money by playing the lottery are minuscule. Investing in the stock market

3 Reasons DexCom Looks Like a No-Brainer Buy Right Now: https://g.foolcdn.com/editorial/images/789980/doctor-talking-to-a-patient-while-making-notes.jpg
3 Reasons DexCom Looks Like a No-Brainer Buy Right Now

DexCom (NASDAQ: DXCM) is a big name in diabetes care. Its continuous glucose monitors (CGMs) help people track their blood glucose levels.

But the stock has been performing poorly this year amid